As we all patiently wait to turn the corner of this health emergency and all that goes with it, many of us are asking ourselves if we’ve already had the Covid -19 Flu Virus.

Were you sick during late 2019 into 2020 with the symptoms that fit the Covid-19 profile ? I have encountered many who’ve answered yes.  We thought it was just a bad flu that was going around since December, while Covid-19 for our area was not prominent on the radar until early March.

Through my membership with Evexia Diagnostics I’m pleased to offer a new serological/antibody test for COVID-19, performed by Evexia’s laboratory partner KBMO Diagnostics, who is testing for IgG and IgM antibodies to the SARS-CoV-2 virus otherwise known as Covid-19.

Dr. Kevin K. Bodling, President & CEO of Evexia; “The COVID-19 Antibody Test has a validated sensitivity of 87.3% and a specificity of 100%, indicating no cross-reactivity with other viruses.” The high performance and fast turn-around time make this test ideally suited for asymptomatic individuals who may have already been infected with SARS-CoV-2 and may now possess immunity.” Dr Bodling is donating 500 antibody tests and 500 PCR swab tests to NYC area hospitals to help with the current crisis.

Antibodies

The IgM and IgG antibody test can provide information on the stage of infection including past infection resulting in probable immunity for one year or more according the the CDC. Both Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies are produced during the primary immune response.

As the body’s largest antibody, IgM is the first antibody to appear in response to an initial exposure to antigens. IgM provides the first line of defense during viral infections, followed by the generation of adaptive, high affinity Immunoglobulin G (IgG) responses for long-term immunity and immunological memory. IgG is usually detectable about 7 days after the IgM appears.

Why Test For Antibodies?

  • Peace Of Mind
    If you suspect past infection, it’s important to know you carry the IgG antibody indicating high probability of immunity for reinfection. Currently, immunity to Covid-19 is believed to be at least 1 year.
  • You are safe not to expose others
  • There will  come a time when it’s important to verify your  immunity.
    Testing lab KBMO will report results to CDC
  • If you suspect recent exposure but are asymptomatic, a positive IgM antibody test will confirm the need for follow up testing.

If you are symptomatic then you need the PCR nasal swab test which is also available through Evexia or through local testing.

And…. you need immediate treatment, which in most cases, is a matter of course for those of us who are experienced natural medicine clinicians. I’m not saying this is not a bad flu. For some it is.  But this is what we do. We have the tools. We don’t prescribe drugs. There are no drugs for this. There are no drugs to impart a healthy immune system. Your intact and resilient immune system is your best defense. It is not widely known that Herbal Medicine and acupuncture became part of the protocol in Wuhan for Covid-19 mid February. They employed it after they found that it worked. More on this to come.

How it works

Home Blood Draw

Contact me to via email or phone to order a kit.

The lab will send a kit 2nd day directly to your home.

We will connect you with a local mobile phlebotomist for you to arrange a blood draw appointment.

Phlebotomist will reiterate  safety precautions for blood draw at time of booking.

After blood draw the phlebotomist will send the kit overnight with the provided  shipping label.

Turn around time for results is 1 – 2 business days from time of receipt.

I will contact you with results and answer your questions.

If your test positive for IgG antibodies, this generally indicates past exposure to or past infection by SARS-CoV-2 virus resulting in  immunity status. Positive IgM antibodies indicates recent or current exposure and a follow up nasal swab can be administered the same way.

Contact me to order a test kit or for a free consultation to review your status with past, present, or suspected infection.

Ph: 305-981-7958

Email: clarkacupuncture@me.com

Total cost to you: $268

Prepayment $228 due at time of order to Clark Acupuncture

Includes kit( $149 )  lab cost & shipping

plus  ( $79 ) facilitation / consult fee

Separate $40 Phlebotomy Fee paid to Mobile Phlebotomy Services

Yours in health,
Nancy Clark,
Licensed Acupuncture Physician

Clark Acupuncture & Functional Wellness

Please note, there are currently NO FDA-Approved COVID-19 Tests of any kind available at this time. All available COVID-19 testing is authorized under the FDA’s Emergency Use Authorization (EUA).

Disclaimer:

  • This test has not been reviewed by the FDA.
  • Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
  • Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
  • Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

As stated in Section IV.A of the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019, for laboratories certified under CLIA to perform high-complexity testing, the FDA does not intend to object to the use of validated tests for specimen testing for a reasonable period of time after validation while the laboratory is preparing an EUA request.

The clinical trial of this test is based on the clear diagnosis/exclusion criteria of the disease identified in the “Novel Coronavirus Pneumonia Diagnosis and Treatment Program“ developed by the Chinese CDC clinical research and was conducted in 5 institutions, the total cases were 447.  Using this kit, 110 cases out of 126 clinically confirmed cases are positive, with the sensitivity of 87.3%; 62 cases of clinically excluded cases are totally negative with the specificity of 100%. The COVID-19 Antibody test we offer has a documented performance of 100% Sensitivity and 100% Specificity.

New Data On Covid-19

A COVID-19 PCR Stool Test should be ordered on patients who have recovered from a confirmed case of SARS-CoV-2/COVID-19.

New data suggests the possibility of extended duration of viral shedding in feces, for nearly 5 weeks after respiratory samples have tested negative for SARS-CoV-2 RNA. Although knowledge about the viability of SARS-CoV-2 is limited, the virus could remain viable in the environment for days, which could lead to fecal–oral transmission. Therefore, routine stool sample testing with real-time RT-PCR is highly recommended after the clearance of viral RNA in a patient’s respiratory samples.

Key Points

  • Cutting-edge viral RNA qPCR stool test measures levels of SARS-CoV-2, the virus that causes COVID-19.
  • Monitor or help prevent transmission in patients at risk for COVID-19.
  • SARS-CoV-2 in stool may be found in up to 53.4% of COVID-19 patients.
  • The virus may be detected in stool for a period of days to weeks after initial infection.
  • Intestinal viral infection may play an important role in COVID-19 disease progression and may increase risk for more severe disease.
  • Detection of SARS-CoV-2 in stool could be used to prevent fecal-oral transmission.

High Fecal Viral Levels Found in COVID-19 Disease and in Asymptomatic Carriers

SARS-CoV-2, the virus that causes COVID-19, can be detected in the stool of up to 53.4% of COVID-19 patients.2-6 In about 23% of cases, patients were no longer positive for the virus in respiratory samples, yet stool samples were still positive,2 clearly underlining the value of fecal testing. Data from 98 COVID-19 patients showed viral shedding in stool for nearly five weeks after respiratory samples were negative.1 Another study reported that patients shed the virus in stool 30 days after initial infection.7

Even asymptomatic carriers may show elevated SARS-CoV-2 in stool.5 Therefore, Wu and colleagues recommend routine RT-PCR stool testing to determine when it is safe to discontinue precautions in recovered COVID-19 patients, so as to prevent transmission of the virus and best allocate medical resources.1

 “… Routine stool sample testing with real-time RT-PCR is highly recommended after the clearance of viral RNA in a patient’s respiratory samples.”1

A Direct Link Between COVID-19 and Gastrointestinal Illness

 “… Routine stool sample testing with real-time RT-PCR is highly recommended after the clearance of viral RNA in a patient’s respiratory samples.”1

A Direct Link Between COVID-19 and Gastrointestinal Illness

SARS-CoV-2 gains entry into the host via the ACE2 protein, which is found not only in lung epithelia, but also gut epithelia. Therefore, the gut could present an entryway into the host and may be a site of viral infection.7 Indeed, two to eighteen percent of patients with COVID-19 had diarrhea, abdominal pain, and vomiting.7,8 Ten percent of patients presented with diarrhea and nausea one to two days before they developed fever and respiratory symptoms.2-6 And in some cases, digestive symptoms were the primary symptom of COVID-19.7 Further, GI symptoms with COVID-19 may indicate a more severe course of illness.7 For example, abdominal pain was reported more frequently in patients admitted to the intensive care unit.6 SARS-CoV-2 can also be detected in fecal specimens of asymptomatic patients.

Identify and Prevent Potential Fecal-Oral Transmission of COVID-19

The presence of SARS-CoV-2 in stool points to a potential fecal-oral transmission route for COVID-19.9 Asymptomatic individuals could therefore spread SARS-CoV-2 unknowingly, although this still remains to be proven. Potential fecal-oral transmission of COVID-19 presents risks for medical personnel having contact with patient stool. Additionally, endoscopic procedures could facilitate the transmission of SARS-CoV-2 through exposure to the virus in gastrointestinal tissues or mucus.10

 The Gut-Lung Axis

The gut microbiome may have a role in lung health. In respiratory tract infections, pathogens invade the airways and multiply. Infection depends on the number and virulence of pathogens, but perhaps more importantly – the host’s defenses.11 Acute respiratory infections such as influenza can initiate dysbiosis in the respiratory and gastrointestinal tracts, which may promote the development of secondary bacterial pneumonias.12 In some studies, oral probiotics have shown protective effects against influenza virus, pneumococcal infections, and ventilator-induced pneumonia.11 This points to a possible strategy of improving the gut microbiome to improve immune defenses and prevent respiratory infections.

 Optimize Gut Health to Reduce the Impact of Coronavirus Infection

Given the role of SARS-CoV-2 in gastrointestinal infection, GI symptoms, and disease severity, a healthy GI tract could reduce infection and/or severity of COVID-19. By optimizing gut health, we may be able to protect patients from further complications caused by SARS-CoV-2.

REFERENCES

  1. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. The lancet Gastroenterology – hepatology.
  2. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. 2020.
  3. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. 2020.
  4. Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. Journal of medical virology.
  5. Xie C, Jiang L, Huang G, et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis.2020;93:264-267.
  6. Tang A, Tong ZD, Wang HL, et al. Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China. Emerg Infect Dis.2020;26(6).
  7. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? The lancet Gastroenterology & hepatology.2020;5(4):335-337.
  8. Pan L, Mu M, Yang P. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. The American journal of gastroenterology.2020;Preproof.
  9. Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci.2020;10:40.
  10. Repici A, Maselli R, Colombo M, et al. Coronavirus (COVID-19) outbreak: what the department of endoscopy should know. Gastrointestinal endoscopy.
  11. Gao Z, Kang Y, Yu J, Ren L. Human pharyngeal microbiome may play a protective role in respiratory tract infections. Genomics Proteomics Bioinformatics.2014;12(3):144-150.
  12. Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory Viral Infection-Induced Microbiome Alterations and Secondary Bacterial Pneumonia. Front Immunol.2018;9:2640.